Crest-2 Registry: Carotid PCI Presents Low Rates of Death and Stroke

Courtesy of Dr. Carlos Fava.

In modern studies, carotid artery stenting (CAS) has been shown equal to surgery in terms of the composite end point of periprocedural stroke, death, acute myocardial infarction and late ipsilateral stroke. This was tested in different groups and by trained operators. 

Protrusión de placa en angioplastia carotidea ¿Qué riesgo implica y cómo prevenirlo?

In the CREST-2 Registry (C2R) 2141 patients were included, 2219 CAS procedures were done by 187 operators in 98 centers across the US.

Mean age was 67.8 years, 65.3% were men who presented high prevalence of risk factors and 55.1% were asymptomatic. Obstruction was 84% and length was 21 mm.

45.5% of procedures were done by interventional cardiologists, 23.5% by vascular surgeons, 13.4% by interventional radiologists / neuroradiologists, 12.3% neurosurgeons and 5.3% by interventional neurologists.


Read also: New Device for More Protection in Carotid Artery Stenting.


All procedures were done with FDA approved stents and protection systems; 94.1% was done with local anesthesia.

At 30 days, global stroke and death rate was 2%, 1.4% for the asymptomatic and 2,8% for the symptomatic.

Conclusion

C2R is the first carotid PCI registry co-sponsored by the Federal Government and the industry. Carotid stenting procedures were carried out by experienced operators with an appropriate selection of patients and an optimal technique. In this environment, with this group of interventional specialists, there was a very low rate of periprocedural stroke and death in patients both symptomatic and asymptomatic. 

Courtesy of Dr. Carlos Fava.

Original Title: Quality Assurance for Carotid Stenting in the CREST-2 Registry.

Reference: Brajesh K. Lal. J Am Coll Cardiol 2019;74:3071–9.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....